vTv Therapeutics(VTVT) - 2024 Q3 - Quarterly Report

Revenue and Financial Performance - The company has not generated any revenue from drug sales to date, relying primarily on milestone payments and collaboration agreements[87]. - Revenue for the nine months ended September 30, 2024, included a $1.0 million increase due to the Newsoara License Agreement, while there was no revenue in the same period of 2023[102]. - The net loss attributable to vTv Therapeutics Inc. for Q3 2024 was$4.8 million, a decrease of $1.9 million compared to a net loss of$6.7 million in Q3 2023[95]. - Net cash used in operating activities increased to $20.5 million for the nine months ended September 30, 2024, compared to$16.2 million in 2023[111]. - Net cash provided by financing activities was $52.6 million for the nine months ended September 30, 2024, significantly up from$12.3 million in 2023[111]. - As of September 30, 2024, the company had cash and cash equivalents of $41.6 million and an accumulated deficit of$296.1 million[108]. Research and Development - Research and development expenses for Q3 2024 were $3.2 million, an increase of$0.4 million or 14.2% compared to $2.8 million in Q3 2023[97]. - Research and development expenses for cadisegliatin were$1.5 million in Q3 2024, down from $1.9 million in Q3 2023[89]. - Research and development expenses decreased by$2.1 million, or 18.7%, to $9.3 million for the nine months ended September 30, 2024, from$11.5 million in 2023[103]. - The lead program, cadisegliatin, received FDA Breakthrough Therapy designation in 2021, supported by positive Phase 2 trial results showing a 40% reduction in severe hypoglycemia[84]. - The FDA placed a clinical hold on the cadisegliatin program on July 26, 2024, requiring further study before resuming trials[84]. - The company plans to initiate two international registrational studies for cadisegliatin in type 1 diabetes, expected to start in 2026[84]. - The company is collaborating with G42 to initiate a Phase 2 trial in the Middle East for type 2 diabetes, anticipated to begin in 2025[85]. Operating Expenses - Total operating expenses for Q3 2024 were $6.5 million, up from$5.4 million in Q3 2023, reflecting an increase of $1.1 million[95]. - General and administrative expenses increased by$1.6 million, or 17.5%, to $11.0 million for the nine months ended September 30, 2024, compared to$9.3 million in 2023[104]. Financing and Capital Requirements - The company closed a private placement financing of up to $51.0 million on February 27, 2024, to advance its lead program for cadisegliatin[108]. - The company entered into a sales agreement with TD Cowen to offer up to$50.0 million of Class A common stock, with $2.5 million already raised[109]. - The company anticipates needing substantial additional funding to continue operations and clinical trials, with future capital requirements dependent on various factors including regulatory approvals and clinical trial progress[113]. Market and Investment Risks - The company does not currently have any material interest rate exposure[120]. - The exposure to market risk is limited to cash and cash equivalents, all with maturities of one year or less[121]. - The investment strategy focuses on capital preservation, liquidity needs, and fiduciary control of cash and investments[121]. - The company seeks to maximize income from investments without assuming significant risk[121]. - There is no material foreign currency exposure reported[122].